# OnCo record her2-amplified-colorectal (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/her2-amplified-colorectal/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "her2-amplified-colorectal" ;
  schema:name "HER2-amplified colorectal cancer"@en ;
  schema:alternateName "HER2-positive colorectal cancer"@en, "ERBB2-amplified colorectal cancer"@en, "HER2-overexpressing bowel cancer"@en ;
  schema:description "A few bowel cancers make too much of the HER2 protein, the same target as in HER2-positive breast cancer. Two HER2 drugs together, tucatinib and trastuzumab, shrink about four in ten of these tumours after chemotherapy has failed, and the antibody-drug conjugate trastuzumab deruxtecan works even when other HER2 drugs have stopped."@en ;
  schema:url <https://onco.cc/cancers/her2-amplified-colorectal/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/HER2/neu> ;
  schema:citation <https://en.wikipedia.org/wiki/HER2/neu>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1428> ;
  onco:tag "subtype-page" ;
  onco:technologies <https://onco.cc/technologies/her2-tyrosine-kinase-inhibitors/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/her2/>, <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/tucatinib/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/pertuzumab/>, <https://onco.cc/drugs/zanidatamab/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/colorectal-cancer-signalling/> ;
  onco:terms <https://onco.cc/terms/sidedness/>, <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/terms/ihc/> ;
  onco:trials <https://onco.cc/trials/mountaineer/>, <https://onco.cc/trials/destiny-crc02/>, <https://onco.cc/trials/mypathway/>, <https://onco.cc/trials/nct05253651/>, <https://onco.cc/trials/nct06695845/>, <https://onco.cc/trials/nct06589830/>, <https://onco.cc/trials/nct06434597/> ;
  onco:people <https://onco.cc/people/tanios-bekaii-saab/> ;
  onco:pipeline <https://onco.cc/trials/nct05253651/>, <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/trials/nct06695845/>, <https://onco.cc/trials/nct06589830/>, <https://onco.cc/trials/nct06434597/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/> ;
  onco:standardOfCare <https://onco.cc/trials/mountaineer/>, <https://onco.cc/drugs/tucatinib/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/pertuzumab/>, <https://onco.cc/technologies/her2-tyrosine-kinase-inhibitors/>, <https://onco.cc/trials/destiny-crc02/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/folfiri/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/trials/nct05253651/> .